Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

i.d.b. radiopharmacy b.v. - lutetium (177lu) chloride - radionuklidų vaizdavimas - terapiniai radiofarmaciniai preparatai - lumark yra radiofarmacinis pirmtakas. jis nėra skirtas pacientams tiesiogiai vartoti. Ši vaistinė medžiaga turi būti naudojama tik radioaktyviai žymint nešiklių molekules, kurios buvo specialiai sukurtos ir leidžiamos radiolabelei su šiuo radionuklidu.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

theratechnologies europe limited - ibalizumab - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - trogarzo, kartu su kitais antiretrovirusinį (- ai), yra nurodyta gydyti suaugusiųjų, užsikrėtusių įvairiems vaistams atsparus Živ-1 infekcijos, už kuriuos jis kitaip neįmanoma statyti, slopinančio antivirusinių režimas.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

itm medical isotopes gmbh - lutetium (177lu) chloride - radionuklidų vaizdavimas - terapiniai radiofarmaciniai preparatai - endolucinbeta yra radioaktyviųjų preparatų pirmtakas, ir jis nėra skirtas pacientams tiesiogiai vartoti. jis turi būti naudojamas tik radioaktyviai žymimoms nešiklių molekulėms, kurios buvo specialiai sukurtos ir patvirtintos radioaktyviam žymėjimui naudojant lutejimo (177lu) chloridą.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

akebia europe limited - geležies citrato koordinavimo kompleksas - hyperphosphatemia; renal dialysis - narkotikai hiperkalemijos ir hiperfosfatemijos gydymui - fekserikas yra skirtas hiperfosfatemijos kontrolei suaugusiems pacientams, sergantiems lėtinės inkstų ligos (ckd).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novo nordisk a/s - katridecakogas - kraujo krešėjimo sutrikimai, paveldimas - antihemoraginiai - ilgalaikis profilaktinis kraujavimo gydymas 6 metų ir vyresniems suaugusiesiems ir vaikams su įgimtu faktoriumi-xiii-a subvieneto trūkumu.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

as kalceks - tramadolio hidrochloridas - injekcinis ar infuzinis tirpalas - 50 mg/ml - tramadol

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

ge healthcare b.v. - natrio molibdatas [99mo] (nešėjo nėra) - radionuklidų generatorius - 2,5-100 gbq - technetium (99mtc) pertechnetate

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - imuninės serumai ir imunoglobulinai, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. Žr. 4 skyrius. 4 ir 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuklidų vaizdavimas - terapiniai radiofarmaciniai preparatai - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.